Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.
EP: 1.An Overview of Neuroblastoma
EP: 2.Approaches to Diagnosing Neuroblastoma
EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma
EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
EP: 5.Differentiating Refractory and Relapsed Neuroblastoma
EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
Now Viewing
EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
EP: 10.Future Perspectives in the Treatment of Neuroblastoma
Related Videos
Related Content
